Please login to the form below

Not currently logged in
Email:
Password:

peglispro

This page shows the latest peglispro news and features for those working in and with pharma, biotech and healthcare.

Lilly's Lantus 'follow-on' approved in the US

Lilly's Lantus 'follow-on' approved in the US

Approval is a boost to Lilly, which decided earlier this month to abandon development of another Lantus rival - insulin peglispro - after concluding data on a potential toxicity issue made the project

Latest news

  • Lilly says insulin peglispro too risky to pursue Lilly says insulin peglispro too risky to pursue

    Lilly says insulin peglispro too risky to pursue. Discontinues development of medicine once tipped as a diabetes blockbuster. ... Eli Lilly has decided to discontinue development of insulin peglispro, a drug once considered a potential blockbuster for

  • Novo Nordisk finally bags insulin degludec approval in US Novo Nordisk finally bags insulin degludec approval in US

    However, there was some good news for Novo Nordisk when it emerged Eli Lilly had delayed filings for its long-acting insulin peglispro candidate after a safety signal was seen in

  • Rivals look to put pressure on Sanofi's Lantus Rivals look to put pressure on Sanofi's Lantus

    The company also released the results of five phase III studies of its long-acting insulin peglispro, which had a serious setback earlier this year when liver fat changes seen in ... However, some of the IMAGINE trials showed an increase in the liver

  • Sanofi wins European approval for Lantus follow-up Toujeo Sanofi wins European approval for Lantus follow-up Toujeo

    However, the company will have slightly longer to establish Toujeo than it originally expected after regulatory filings for Lilly's insulin peglispro were delayed recently due to safety concerns.

  • FDA starts review of Novo's refiled diabetes pair FDA starts review of Novo's refiled diabetes pair

    Until recently, additional competition was also looming in the form of Lilly's long-acting insulin peglispro, although that project has now been significantly delayed after fatty liver changes were seen

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics